444 SVR for Controlled-Release Interferon Alpha-2b (Cr2b) +Ribavirin Compared to Pegylated Interferon Alpha-2b (Peg2b) +Ribavirin in Treatment-Naive Genotype-1 (G1) Hepatitis C: Final Results From Select-2

Läwitz, E.; Younossi, Zobair M.; Mehra, Rakesh; Rigney, A.; Krastev, Zahary; Tchernev, К.; Takov, D.; Long, W.A.

doi:10.1016/s0168-8278(11)60446-7

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The EMPOWER trial and SELECT‐2 trials noted that CR2b not only achieved non‐inferiority but also reduced flu symptoms by 50% (30,31).…”

Section: Resultsmentioning

confidence: 99%

New therapies for chronic hepatitis C infection: a systematic review of evidence from clinical trials

Lee¹,

Tong²,

Wong³

et al. 2012

International Journal of Clinical Practice

View full text Add to dashboard Cite

Summary Introduction: Hepatitis C virus (HCV) affects approximately 3% of the world population. The current standard of care for treatment of HCV is a combination of pegylated interferon and ribavirin. Approximately 10% of patients will stop treatment and 30% of patients require dose reduction because of side effects. For genotype 1 HCV‐infected patients, only 40% of patients will achieve undetectable viral load 26 weeks posttreatment. Aims: The objectives of this review were to identify new treatments that are in clinical trials. These include boceprevir and telaprevir which are in routine clinical use and form part of the American Association for the Study of Liver Diseases (AASLD) 2011 guidelines as well as drugs based on observational studies, improving/modifying ribavirin or interferon‐based therapies, modifying the host response and finally the use of direct‐acting antiviral agents (DAA). Materials and methods: MEDLINE and EMBASE databases were searched from 2008 to 2011 for treatments for hepatitis C. Furthermore, abstracts and poster presentations for the annual European Association Study of the Liver, AASLD, Digestive Disease Week and Asian Pacific Association for the study of the Liver were searched for relevant material. Results: All four classes of DAA; NS3/NS4a serine protease inhibitors, cyclophilin inhibitors, NS5b polymerase inhibitors and NS5a inhibitors, show good success rates. Trials have been performed without ribavirin or interferon and demonstrate good antiviral activity with a decreased side effect profile. Combinations of DAA are a promising area of research with a high success rate. Conclusions: Clinical trials show that future HCV therapy could be personalised, achieve higher success rates with decreased adverse incidents.

show abstract

“…The EMPOWER trial and SELECT‐2 trials noted that CR2b not only achieved non‐inferiority but also reduced flu symptoms by 50% (30,31).…”

Section: Resultsmentioning

confidence: 99%

New therapies for chronic hepatitis C infection: a systematic review of evidence from clinical trials

Lee¹,

Tong²,

Wong³

et al. 2012

International Journal of Clinical Practice

View full text Add to dashboard Cite

show abstract

“…Режим дозирования -1 раз в 2 нед -может оказаться весьма перспективной альтернативой по сравнению с другими ИФН в лечении ХГС у детей [63]. Проведенные испытания показали, что контролируемое высвобождение ИФН α-2b, наблюдаемое при использовании этого препарата, сопровождается не только сопоставимой эффективностью лечения, но и уменьшает гриппоподобные симптомы при проведении лечения на 50% [64,65].…”

Section: современный взгляд на терапию хронического гепатита с у детей: прошлое настоящее перспективы будущегоunclassified

Chronic Hepatitis C in Children: Problems and Prospects

Потапов

2014

ARAMS

View full text Add to dashboard Cite

The analysis of a problem state of chronic hepatitis C in children was conducted. Data on primary incidence of chronic hepatitis C at the children's population as on the territory of the Russian Federation, and abroad are submitted. Problems of diagnosis of a HCV infection are studied. The survey analysis of risk of contamination is carried out, possible ways of transfer are highlighted, features of a course of a HCV infection in children are shown, synchronising frequency of a process is displayed. The problem is analysed now, and further prospects in treatment of chronic viral hepatitis C in children are estimated.

show abstract

Treatment of children with chronic viral hepatitis: what is available and what is in store

et al. 2013

View full text Add to dashboard Cite

show abstract

444 SVR for Controlled-Release Interferon Alpha-2b (Cr2b) +Ribavirin Compared to Pegylated Interferon Alpha-2b (Peg2b) +Ribavirin in Treatment-Naive Genotype-1 (G1) Hepatitis C: Final Results From Select-2

Cited by 4 publications

References 0 publications

New therapies for chronic hepatitis C infection: a systematic review of evidence from clinical trials

New therapies for chronic hepatitis C infection: a systematic review of evidence from clinical trials

Chronic Hepatitis C in Children: Problems and Prospects

Treatment of children with chronic viral hepatitis: what is available and what is in store

Contact Info

Product

Resources

About